LG Chem to acquire AVEO Oncology with USD $566 million investment
![](/46/pdcnewsitem/11/91/14/CPHI%20online%20images%20(31).png)
South Korean chemical company LG Chem is set to acquire AVEO Oncology, an oncology-focused biopharmaceutical company based in the USA, as part of an investment to increase its footprint in North America and expand its development and commercialisation offerings.
LG Chem (Seoul, South Korea) has announced a definitive agreement with AVEO Oncology (AVEO, Cambridge, USA) in which LG Chem will acquire AVEO at USD $15.00 per share with an implied equity value of USD $566 million.
AVEO, a commercial-stage oncology biopharmaceutical company, will join LG Chem’s Life Sciences division to create a global oncology organisation. The acquisition hopes to bring a robust portfolio of innovative products with support for all stages of therapeutic development, from discovery to clinical, biologics manufacturing and US commercialisation at scale. LG Chem Life Sciences is expected to increase its North American footprint in the US, diversifying its pipeline with the range of oncology therapies provided by AVEO, accelerating LG Chem’s efforts to offer the development and commercialisation of cancer therapies.
AVEO’s leading product FOTIVDA, a US FDA approved treatment for adult patients with relapsed or refractory advanced renal cell carcinoma, will establish LG Chem’s commercial presence as well as granting AVEO access to greater resources for therapeutic development and commercialisation. The transaction is hoped to expand the company’s pipelines in oncology in bringing cancer therapies to those who need them most. LG Chem is currently actively advancing several clinical and preclinical stage anti-cancer therapies, and will be able to become a fully integrated pharmaceutical company with the acquisition.
Commenting on the acquisition, CEO of LG Chem Shin Hak-Cheol states: “With its track record of clinical success, deep pipeline of innovative therapies, and continued growth trajectory following the successful commercialisation of FOTIVDA, AVEO is the perfect partner for LG Chem Life Sciences... This transaction represents the next step in our portfolio transformation towards higher growth markets and provides a strong commercial foundation in oncology as we continue to develop our anti-cancer offerings.”
President and CEO of AVEO Michael Bailey added: “By joining forces with LG Chem, AVEO expects to have significant financial and development resources to help AVAEO fully realise the tremendous potential of our promising pipeline. LG Chem shares AVEO’s deep commitment to patients and vision of developing innovative therapies designed to provide substantial impact in the lives of cancer patients with clear, unmet medical needs. This transaction is a testament to the extraordinary efforts of our employees, who will play an integral role in the success of the combined company. We look forward to entering our next chapter of growth with the support of LG Chem.”
Source: LG Chem to Acquire AVEO Oncology for $15.00 Per Share in (globenewswire.com)
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance